COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group

Area of Science:

• Hematology
• Infectious Diseases
• Oncology

Background:

• Chronic lymphocytic leukemia (CLL) patients exhibit heightened vulnerability to adverse outcomes from COVID-19.
• Understanding the specific impact of COVID-19 on this immunocompromised population is crucial for clinical management.

Purpose of the Study:

• To evaluate the effects of COVID-19 infection on CLL patients in the Czech Republic.
• To identify risk factors associated with mortality in CLL patients diagnosed with COVID-19.

Main Methods:

• A multicenter cohort study was conducted between March 2020 and May 2021.
• Data from 341 CLL patients with COVID-19 were analyzed, including demographics, treatment history, COVID-19 severity, and outcomes.

Main Results:

• The overall case fatality rate was 28%.
• Factors associated with increased mortality included older age (>72 years), male gender, history of CLL therapy, and active CLL treatment at COVID-19 diagnosis.
• Bruton tyrosine kinase inhibitor (BTKi) therapy showed no outcome advantage over chemoimmunotherapy (CIT).

Conclusions:

• COVID-19 poses a significant threat to CLL patients, with a substantial mortality rate.
• Prognostic factors for poor outcomes in this cohort were identified, highlighting the need for vigilant monitoring and tailored care.
• Current CLL treatment strategies, including BTKi and CIT, did not demonstrate differential impact on COVID-19 survival in this study.